Results 291 to 300 of about 1,080,358 (387)
ESC Heart Failure, EarlyView.Abstract Aims Angiotensin receptor‐neprilysin inhibitor (ARNI) therapy has demonstrated improved outcomes in heart failure with reduced ejection fraction (HFrEF). However, its benefits in patients with concomitant kidney failure undergoing replacement therapy remain uncertain. Methods and results Using the National Health Insurance Service database, we
Mi‐Hyang Jung +8 more
wiley +1 more source
An unusual presentation of pheochromocytoma accompanied by catecholamine‐induced cardiomyopathy
ESC Heart Failure, EarlyView.
Hugh O.J. Roberts +2 more
wiley +1 more source
Immuno‐haemostatic dysregulation in heart failure with preserved ejection fraction
ESC Heart Failure, EarlyView.Abstract Aims Heart failure with preserved ejection fraction (HFpEF) is a complex condition with partially unclear pathophysiology, in which systemic inflammation is a central contributor to changes in cardiac structure and function. The contribution of non‐traditional immune effectors—such as platelets and coagulation—remains underexplored in HFpEF ...
Giorgia D'Italia +13 more
wiley +1 more source
Impact of Natriuretic Peptide on the Evolution of Patients With Pulmonary Embolism and Neoplasm. [PDF]
CureusNemtut DM +6 more
europepmc +1 more source
ESC Heart Failure, EarlyView.Abstract Aims Targeting inflammasomes in heart failure (HF) might represent a novel therapeutic option. Nevertheless, previous studies focused only on myocardial inflammasome alterations, and data are scarce regarding their regulation and role in HF‐associated multiorgan dysfunction.
Dávid Nagy +12 more
wiley +1 more source
Natriuretic Peptide Levels in Acute Heart Failure Patients With Atrial Fibrillation Versus Sinus Rhythm: Challenging Conventional Understanding. [PDF]
Int J Heart FailBae DH.
europepmc +1 more source